Efficacy and Safety Profile of Long Term Exposure to Lenalidomide in Relapsed Multiple Myeloma.
Guillemette Fouquet(Centre Hospitalier Universitaire de Lille), Xavier Leleu(Inserm), Suzanne Robinson(Bristol-Myers Squibb (Switzerland)), Thierry Façon(Université de Lille), Sarah Bonnet(Hôpital Saint Eloi), Caroline Serrier(Hôpital Lyon Sud), Pascale Morel(Bristol-Myers Squibb (Switzerland)), Charles Herbaux(Centre Hospitalier Universitaire de Lille), Houria Debarri(Centre Hospitalier Universitaire de Lille), Julie Gay(Centre Hospitalier de la Côte Basque), Hervé Avet‐Loiseau(Institut universitaire du cancer de Toulouse Oncopole), Stéphanie Tardy(Centre Hospitalier Régional et Universitaire de Nancy), Aurore Perrot(Institut universitaire du cancer de Toulouse Oncopole), Jessica Michel(Centre Hospitalier Régional et Universitaire de Nancy), Cyrille Hulin(Centre Hospitalier Régional et Universitaire de Nancy), Hélène Demarquette(Ikerbasque), Darko Miljkovic(Bristol-Myers Squibb (Switzerland)), Catherine Boccacio(Hôpital Cochin)
Cited by 0
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
|Nature Communications|2014|906